Recurrent respiratory papillomatosis: update 2018

  title={Recurrent respiratory papillomatosis: update 2018},
  author={Craig S Derkay and Andrew E Bluher},
  journal={Current Opinion in Otolaryngology \& Head and Neck Surgery},
Purpose of review Recurrent respiratory papillomatosis (RRP) is the most common as well as the costliest benign airway neoplasm in the United States [Ivancic et al. (2018). Laryngoscope Investig Otolaryngol 3:22; Derkay (1995). Arch Otolaryngol Head Neck Surg 121:1386]. In addition, it is potentially deadly, with risk of airway obstruction as well as a 3–7% risk of malignant conversion [Schraff et al. (2004). Arch Otolaryngol Head Neck Surg 130:1039]. This review highlights exciting… 
Pediatric Laryngeal Papillomatosis: Experiences at an Indian Teaching Hospital
Coblation and microdebrider were found to be safe and cost-effective than laser and coblation and common and effective techniques performed among children with laryngeal papillomatosis.
High recurrence rate in patients with juvenile-onset respiratory papillomatosis and its risk factors
Age at diagnosis younger than 4.5 years, high Derkay anatomical score and HPV type 11 infection were associated with an increased risk for recurrence in patients with JORRP, and adjuvant therapy with interferon may reduce the risk of recurrence.
Tracheotomy as a predictor of remission and demise for juvenile-onset recurrent respiratory papillomatosis
The age at diagnosis, the surgical frequency and the medical level of hospital are important factors affecting the occurrence of tracheotom, and patients who had undergone tracheotomy are prone to possess the low remission rate and high mortality.
Evaluation of Safety of Intralesional Cidofovir for Adjuvant Treatment of Recurrent Respiratory Papillomatosis.
In this cohort of patients with RRP, adjuvant intralesional cidofovir injections did not appear to cause major complications or an increased rate of development of dysplasia and cancer.
Systemic bevacizumab for recurrent respiratory papillomatosis.
Pembrolizumab Induced Acute Persistent Airway Disease in a Patient with Recurrent Respiratory Papillomatosis (RRP)
This case is the first report of pembrolizumab-induced obstructive respiratory failure in a patient being treated for RRP, and the underlying asthma remains poorly controlled.
Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial.
The frequency of RRP recurrences was significantly lower after HPV vaccination, and patients with RRP thus had a reduced burden of disease.
A Novel In Vivo Model of Laryngeal Papillomavirus-Associated Disease Using Mus musculus Papillomavirus
This first report of laryngeal MmuPV1 infection provides a foundation for a preclinical model of RRP, and it is confirmed that experimentally induced injury is dispensable for larynGEal M muPV 1 infection and disease in immunocompromised mice.


Recurrent respiratory papillomatosis: update 2008
Despite several new therapies discussed in this study, RRP is still a disease with the potential for high morbidity and it will take many years to determine whether prevention strategies are effective in limiting the spread of this disease.
Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases
Two cases of extensive airway and parenchymal RRP successfully managed with systemically administered bevacizumab, a recombinant monoclonal antibody that inhibits VEGF are presented.
Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child
This is a case report of a 12‐year‐old female diagnosed with severe laryngotracheal papillomatosis near birth who underwent a tracheostomy tube placement at 1 year of age and has had no major or minor complication from the chemotherapy to date.
Recurrent respiratory papillomatosis (RRP)–time for a reckoning?
The aim of this study was to determine if adjuvant vaccination with the quadrivalent HPV L1 vaccine (Gardasil™) would decrease numbers of surgical treatments post‐ vaccination.
Task force on recurrent respiratory papillomas. A preliminary report.
  • C. Derkay
  • Medicine
    Archives of otolaryngology--head & neck surgery
  • 1995
A registry of patients with recurrent respiratory papillomas would benefit future research protocols and provide long-term follow-up of patients.
American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy.
There has been an evolution in the past decade toward the increased use of antiviral adjuvant therapy and the use of microdebrider techniques for surgical management.
Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report.
Pegylated interferon may be a good option for diminishing the need for surgical intervention in severe cases of recurrent respiratory papillomatosis.
Current and future management of recurrent respiratory papillomatosis
This review provides perspectives on current and future management of RRP, a chronic disease of the respiratory tract that occurs in both children and adults.